Precigen, Inc. (PGEN)
PGEN Stock Price Chart
Explore Precigen, Inc. interactive price chart. Choose custom timeframes to analyze PGEN price movements and trends.
PGEN Company Profile
Discover essential business fundamentals and corporate details for Precigen, Inc. (PGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Aug 2013
Employees
143.00
Website
https://www.precigen.comCEO
Helen Sabzevari
Description
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
PGEN Financial Timeline
Browse a chronological timeline of Precigen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.02, while revenue estimate is $27.98m.
Earnings released on 13 May 2026
EPS came in at -$0.02 surpassing the estimated -$0.03 by +33.33%, while revenue for the quarter reached $23.25m , beating expectations by +11.75%.
Earnings released on 25 Mar 2026
EPS came in at -$0.01 surpassing the estimated -$0.10 by +90.00%, while revenue for the quarter reached $4.58m , missing expectations by -45.56%.
Earnings released on 13 Nov 2025
EPS came in at -$0.11 falling short of the estimated -$0.08 by -37.50%, while revenue for the quarter reached $2.92m , missing expectations by -64.73%.
Earnings released on 12 Aug 2025
EPS came in at -$0.11 surpassing the estimated -$0.14 by +21.43%, while revenue for the quarter reached $856.00k , missing expectations by -8.29%.
Earnings released on 14 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%, while revenue for the quarter reached $1.34m , beating expectations by +168.20%.
Earnings released on 19 Mar 2025
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $1.19m , beating expectations by +62.27%.
Earnings released on 14 Nov 2024
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $953.00k , missing expectations by -26.69%.
Earnings released on 14 Aug 2024
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $717.00k , missing expectations by -43.98%.
Earnings released on 14 May 2024
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $1.07m , missing expectations by -28.04%.
Earnings released on 19 Mar 2024
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $1.23m , missing expectations by -42.47%.
Earnings released on 9 Nov 2023
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $1.38m , missing expectations by -18.88%.
Earnings released on 9 Aug 2023
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%, while revenue for the quarter reached $1.77m , missing expectations by -18.94%.
Earnings released on 10 May 2023
EPS came in at -$0.10 falling short of the estimated -$0.08 by -25.00%, while revenue for the quarter reached $1.85m , missing expectations by -16.62%.
Earnings released on 6 Mar 2023
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%, while revenue for the quarter reached $1.76m , missing expectations by -71.61%.
Earnings released on 9 Nov 2022
EPS came in at -$0.04 falling short of the estimated $0.10 by -140.00%, while revenue for the quarter reached $16.72m , beating expectations by +514.78%.
Earnings released on 8 Aug 2022
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $2.91m , missing expectations by -87.08%.
Earnings released on 9 May 2022
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $32.02m , beating expectations by +13.05%.
Earnings released on 1 Mar 2022
EPS came in at -$0.13 surpassing the estimated -$0.14 by +7.14%, while revenue for the quarter reached $24.22m , missing expectations by -0.34%.
Earnings released on 8 Nov 2021
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%, while revenue for the quarter reached $21.56m , missing expectations by -9.64%.
Earnings released on 9 Aug 2021
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%, while revenue for the quarter reached $3.82m , missing expectations by -88.64%.
PGEN Stock Performance
Access detailed PGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
